Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2025-02-27 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
关于诉讼的进展公告
Legal Proceedings Report Classification · 100% confidence The document is an announcement regarding the progress of a legal lawsuit involving the company Harbin Yuheng Pharmaceutical Co., Ltd. It details the litigation stage, parties involved, amounts in dispute, and the impact on the company's profits. It references court decisions and appeals but does not contain financial statements or detailed financial data. The document is a legal proceeding update rather than a financial report or other filing type. Therefore, it fits the category of Legal Proceedings Report (LTR). The document length is short and focused on litigation information, confirming this classification.
2025-02-27 Chinese
公司章程（2025年2月）
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association (章程) for Harbin Gloria Pharmaceuticals Co., Ltd., including comprehensive sections on company organization, shareholder rights, board structure, share issuance, shareholder meetings, and governance rules. It references Chinese company law and securities law, and covers topics such as share issuance, shareholder meetings, board and management roles, financial accounting, audit, and legal compliance. The document is lengthy (15,000 characters) and contains substantive governance and organizational rules rather than financial results or announcements. It is not an annual report, earnings release, or any financial statement. It is not a notice or announcement but a formal governance document outlining the company's internal rules and structure. Therefore, it fits the category of Governance Information (CGR).
2025-02-27 Chinese
第七届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding resolutions passed at the company's seventh board of directors second meeting. It includes details about amendments to the company's articles of association, appointment of the legal representative, nomination of a new non-independent director candidate, and the decision to convene the 2025 second extraordinary general meeting. The document contains voting results and procedural compliance statements. It does not contain financial statements or detailed financial data, nor is it a transcript or presentation. It is an official announcement of board decisions and management changes, specifically about board composition and legal representative changes. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 3629 characters, which is relatively short and consistent with an announcement rather than a full report. Hence, the classification is MANG with high confidence.
2025-02-27 Chinese
关于召开2025年第二次临时股东大会的通知
Regulatory Filings Classification · 95% confidence The document is a notice about convening the 2025 second extraordinary general meeting of shareholders for Harbin Gloria Pharmaceuticals Co., Ltd. It includes details about the meeting time, location, agenda items (such as amendments to the company charter, appointment of legal representative, and election of a director), voting procedures including online voting, and proxy authorization forms. There are no financial statements or financial performance data presented. The document is primarily an announcement informing shareholders about the meeting and how to participate and vote. It is not a report like an annual or interim report, nor is it a voting results announcement or a proxy solicitation statement. Given the content and length (4149 characters), it fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about the shareholder meeting and related procedures.
2025-02-27 Chinese
第七届董事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from Harbin Gloria Pharmaceuticals Co., Ltd. regarding the resolutions passed at the first meeting of the seventh board of directors. It includes details about the election of the chairman, appointment of board committees, and hiring of senior management personnel. The document also provides detailed biographies of the newly appointed directors and senior executives. There is no financial data, earnings information, or regulatory filings related to financial performance. Instead, the content focuses on changes in the company's board and senior management. Therefore, this document fits the category of Board/Management Information (MANG). The document length (7007 characters) and detailed content support this classification with high confidence.
2025-02-06 Chinese
关于回购注销部分限制性股票减少注册资本暨通知债权人的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement by Harbin Gloria Pharmaceuticals Co., Ltd. regarding the repurchase and cancellation of restricted shares, which leads to a reduction in registered capital. It also notifies creditors about their rights to claim debts or request guarantees within a specified period. The document includes details about the board and shareholder meetings that approved the repurchase, the number of shares involved, and instructions for creditors to submit claims. The content is focused on a corporate action related to share repurchase and capital reduction, with a creditor notification component. It is not a full financial report, earnings release, or management discussion. It is also not a simple announcement of a report publication but a substantive announcement about a capital change event. Therefore, the most appropriate classification is "Transaction in Own Shares (POS)" because it involves the company buying back and canceling its own shares, reducing capital accordingly.
2025-02-06 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.